drugset / Trial / NCT07285265

Phase I Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above

NCT07285265

RandomizedParallel-groupTriple-blindPrevention

Summary

The primary objective of this study is to evaluate the tolerability, reactogenicity and safety of 2 injections (approximately 2 months apart) of three different dose levels of ABO1108 in adults aged 40 years or above.

Timeline

Start
2025-05-27
Primary completion
2025-11-06
Completion
2026-10-15

Drugs

EvaluationDrugModalityDoseRoute
Subject ABO1108 Messenger RNA (mRNA)
Subject VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E Vaccine